BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 30358050)

  • 1. Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: A meta-analysis with bias analysis.
    Morrison AE; Zaccardi F; Khunti K; Davies MJ
    Liver Int; 2019 Mar; 39(3):557-567. PubMed ID: 30358050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission.
    Wild SH; Walker JJ; Morling JR; McAllister DA; Colhoun HM; Farran B; McGurnaghan S; McCrimmon R; Read SH; Sattar N; Byrne CD;
    Diabetes Care; 2018 Feb; 41(2):341-347. PubMed ID: 29167212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
    Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP
    World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of effects of obesity and non-alcoholic fatty liver disease on incidence of type 2 diabetes mellitus.
    Li WD; Fu KF; Li GM; Lian YS; Ren AM; Chen YJ; Xia JR
    World J Gastroenterol; 2015 Aug; 21(32):9607-13. PubMed ID: 26327768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis.
    Mantovani A; Csermely A; Petracca G; Beatrice G; Corey KE; Simon TG; Byrne CD; Targher G
    Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):903-913. PubMed ID: 34555346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-alcoholic fatty liver disease (NAFLD) and 10-year risk of cardiovascular diseases.
    Motamed N; Rabiee B; Poustchi H; Dehestani B; Hemasi GR; Khonsari MR; Maadi M; Saeedian FS; Zamani F
    Clin Res Hepatol Gastroenterol; 2017 Feb; 41(1):31-38. PubMed ID: 27597641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study.
    Kim KS; Hong S; Han K; Park CY
    BMJ; 2024 Feb; 384():e076388. PubMed ID: 38350680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis.
    Targher G; Byrne CD; Lonardo A; Zoppini G; Barbui C
    J Hepatol; 2016 Sep; 65(3):589-600. PubMed ID: 27212244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases.
    Adams LA; Anstee QM; Tilg H; Targher G
    Gut; 2017 Jun; 66(6):1138-1153. PubMed ID: 28314735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk.
    Caussy C; Aubin A; Loomba R
    Curr Diab Rep; 2021 Mar; 21(5):15. PubMed ID: 33742318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic increase in cardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease: a meta-analysis.
    Zhou YY; Zhou XD; Wu SJ; Hu XQ; Tang B; Poucke SV; Pan XY; Wu WJ; Gu XM; Fu SW; Zheng MH
    Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):631-636. PubMed ID: 29351115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalences of Hypertension, Type 2 Diabetes Mellitus, and Cardiovascular Disease in a Cohort of Puerto Ricans with Non-alcoholic Fatty Liver Disease.
    González-Rivera A; Vargas-Figueroa VM; Candal-Rivera E; Torres EA
    P R Health Sci J; 2024 Mar; 43(1):18-24. PubMed ID: 38512757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of BMI with cardiovascular disease incidence and mortality in patients with type 2 diabetes mellitus: A systematic review and dose-response meta-analysis of cohort studies.
    Zhao Y; Qie R; Han M; Huang S; Wu X; Zhang Y; Feng Y; Yang X; Li Y; Wu Y; Liu D; Hu F; Zhang M; Sun L; Hu D
    Nutr Metab Cardiovasc Dis; 2021 Jun; 31(7):1976-1984. PubMed ID: 33965298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between non-alcoholic fatty liver disease and impaired cardiac sympathetic/parasympathetic balance in subjects with and without type 2 diabetes-The Cooperative Health Research in South Tyrol (CHRIS)-NAFLD sub-study.
    Targher G; Mantovani A; Grander C; Foco L; Motta B; Byrne CD; Pramstaller PP; Tilg H
    Nutr Metab Cardiovasc Dis; 2021 Nov; 31(12):3464-3473. PubMed ID: 34627696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
    Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies.
    Jarvis H; Craig D; Barker R; Spiers G; Stow D; Anstee QM; Hanratty B
    PLoS Med; 2020 Apr; 17(4):e1003100. PubMed ID: 32353039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic fatty liver disease - A multisystem disease?
    Mikolasevic I; Milic S; Turk Wensveen T; Grgic I; Jakopcic I; Stimac D; Wensveen F; Orlic L
    World J Gastroenterol; 2016 Nov; 22(43):9488-9505. PubMed ID: 27920470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular risk factors in non-alcoholic fatty liver disease.
    Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Askling J; Hultcrantz R; Kechagias S
    Liver Int; 2019 Jan; 39(1):197-204. PubMed ID: 30253056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-alcoholic fatty liver disease, metabolic goal achievement with incident cardiovascular disease and eGFR-based chronic kidney disease in patients with prediabetes and diabetes.
    Li M; Zhao Z; Qin G; Chen L; Lu J; Huo Y; Chen L; Zeng T; Xu M; Chen Y; Wang T; Wang S; Xu Y; Shi L; Tang X; Su Q; Yu X; Yan L; Wan Q; Chen G; Gao Z; Wang G; Shen F; Luo Z; Zhang Y; Liu C; Wang Y; Hu R; Ye Z; Wu S; Deng H; Yang T; Li Q; Qin Y; Mu Y; Zhao J; Ning G; Bi Y; Xu Y; Wang W
    Metabolism; 2021 Nov; 124():154874. PubMed ID: 34517014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.
    Younossi ZM; Golabi P; de Avila L; Paik JM; Srishord M; Fukui N; Qiu Y; Burns L; Afendy A; Nader F
    J Hepatol; 2019 Oct; 71(4):793-801. PubMed ID: 31279902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.